Recent advances in the molecular pathophysiology of atrial fibrillation

Journal of Clinical Investigation

Volumn 121, Issue 8, 2011, Pages 2955-2968

  Wakili, Reza ^a,b   Voigt, Niels ^c   Kääb, Stefan ^b   Dobrev, Dobromir ^c   Nattel, Stanley ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE; CALCIUM DEPENDENT POTASSIUM CURRENT INHIBITOR; CALCIUM ION; CALMODULIN DEPENDENT KINASE II; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OMEGA 3 FATTY ACID; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KCNH2; POTASSIUM CHANNEL KCNQ1; RYANODINE RECEPTOR 2; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SODIUM CALCIUM EXCHANGE PROTEIN; SODIUM CHANNEL NAV1.5; SODIUM ION; TRANSCRIPTION FACTOR PITX2; UNCLASSIFIED DRUG;

AGING; ATRIAL FIBROSIS; CALCIUM TRANSPORT; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; ECTOPIA CORDIS; ENZYME SUBSTRATE; GENE CONTROL; GENETIC PREDISPOSITION; HEART ATRIUM FIBRILLATION; HEART CONDUCTION; HEART DEPOLARIZATION; HEART MUSCLE FIBROSIS; HEART MUSCLE POTENTIAL; HEREDITY; HUMAN; HYPERTENSION; INTRACELLULAR SIGNALING; LOSS OF FUNCTION MUTATION; MOLECULAR PATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REENTRY ARRHYTHMIA; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VALVULAR HEART DISEASE;

EID: 79960985606     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI46315     Document Type: Review

References (150)

1. Miyasaka Y, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119-125. (Pubitemid 44420743)
2. Dobrev D, Nattel S. New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet. 2010; 375(9721):1212-1223.
3. Nattel S. From guidelines to bench: implications of unresolved clinical issues for basic investigations of atrial fibrillation mechanisms. Can J Cardiol. 2011;27(1):19-26.
4. Nattel S. New ideas about atrial fibrillation 50 years on. Nature. 2002;415(6868):219-226. (Pubitemid 34059528)
5. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol. 2008;1(1):62-73.
6. Dobrev D, Voigt N, Wehrens XH. The ryanodine receptor channel as a molecular motif in atrial fibrillation: pathophysiological and therapeutic implications. Cardiovasc Res. 2011;89(4):734-743.
7. MacLennan DH, Chen SR. Store overload-induced Ca2+ release as a triggering mechanism for CPVT and MH episodes caused by mutations in RYR and CASQ genes. J Physiol. 2009;587(pt 13):3113-3115.
8. Berenfeld O, Zaitsev AV, Mironov SF, Pertsov AM, Jalife J. Frequency-dependent breakdown of wave propagation into fibrillatory conduction across the pectinate muscle network in the isolated sheep right atrium. Circ Res. 2002;90(11):1173-1180. (Pubitemid 34786902)
9. Haissaguerre M, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339(10):659-666. (Pubitemid 28402090)
10. Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol. 2008;51(8):802-809. (Pubitemid 351260071)
11. Allessie MA, et al. Pathophysiology and prevention of atrial fibrillation. Circulation. 2001;103(5):769-777. (Pubitemid 32144209)
12. Kozlowski D, et al. Lone atrial fibrillation: what do we know? Heart. 2010;96(7):498-503.
13. Mukamal KJ, Tolstrup JS, Friberg J, Jensen G, Gronbaek M. Alcohol consumption and risk of atrial fibrillation in men and women: the Copenhagen City Heart Study. Circulation. 2005;112(12):1736-1742. (Pubitemid 41368149)
14. Auer J, Scheibner P, Mische T, Langsteger W, Eber O, Eber B. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J. 2001;142(5):838-842. (Pubitemid 33016203)
15. Schoonderwoerd BA, Smit MD, Pen L, Van Gelder IC. New risk factors for atrial fibrillation: causes of "not-so-lone atrial fibrillation." Europace. 2008;10(1):668-673. (Pubitemid 351775282)
16. Chou CC, Chen PS. New concepts in atrial fibrillation: neural mechanisms and calcium dynamics. Cardiol Clin. 2009;27(1):35-43, viii.
17. Mahida S, Lubitz SA, Rienstra M, Milan DJ, Ellinor PT. Monogenic atrial fibrillation as pathophysiological paradigms. Cardiovasc Res. 2011;89(4):692-700.
18. Sinner M, Ellinor PT, Meitinger T, Benjamin EJ, Kääb S. Genome-wide association studies: past, present, and future. Cardiovasc Res. 2011;89(4):701-709.
19. Gaborit N, et al. Human atrial ion channel and transporter subunit gene-expression remodeling associated with valvular heart disease and atrial fibrillation. Circulation. 2005;112(4):471-481. (Pubitemid 41060786)
20. Hove-Madsen L, et al. Atrial fibrillation is associated with increased spontaneous calcium release from the sarcoplasmic reticulum in human atrial myocytes. Circulation. 2004;110(11):1358-1363. (Pubitemid 39238013)
21. Vest JA, et al. Defective cardiac ryanodine receptor regulation during atrial fibrillation. Circulation. 2005;111(16):2025-2032. (Pubitemid 40577896)
22. Liang X, et al. Ryanodine receptor-mediated Ca2+ events in atrial myocytes of patients with atrial fibrillation. Cardiology. 2008;111(2):102-110.
23. 2+ levels in right atrial myocardium of patients with atrial fibrillation. Circ Res. 2010;106(6):1134-1144.
24. 2+ leak promotes atrial fibrillation in mice. J Clin Invest. 2009;119(7):1940-1951.
25. Greiser M, et al. Distinct contractile and molecular differences between two goat models of atrial dysfunction: AV block-induced atrial dilatation and atrial fibrillation. J Mol Cell Cardiol. 2009;46(3):385-394.
26. Sood S, et al. Intracellular calcium leak due to FKBP12.6 deficiency in mice facilitates the inducibility of atrial fibrillation. Heart Rhythm. 2008;5(7):1047-1054.
27. Gassanov N, Brandt MC, Michels G, Lindner M, Er F, Hoppe UC. Angiotensin II-induced changes of calcium sparks and ionic currents in human atrial myocytes: potential role for early remodeling in atrial fibrillation. Cell Calcium. 2006;39(2):175-186. (Pubitemid 43013849)
28. 2+ handling in human chronic atrial fibrillation. Circulation. 2006;114(7):670-680.
29. 2+ release in right atrial myocytes from experimental persistent atrial fibrillation. Circ Res. 2009;105(9):876-885.
30. 2+ signaling is abolished in atrial myocytes of inositol-1,4,5- trisphosphate(IP3)-receptor type 2-deficient mice. Circ Res. 2005;96(12):1274-1281.
31. Zhao ZH, et al. Inositol-1,4,5-trisphosphate and ryanodine-dependent Ca2+ signaling in a chronic dog model of atrial fibrillation. Cardiology. 2007;107(4):269-276.
32. 2+ signalling in cat atrial excitation-contraction coupling and arrhythmias. J Physiol. 2004;555(pt 3):607-615.
33. Ehrlich JR, Nattel S, Hohnloser SH. Atrial fibrillation and congestive heart failure: specific considerations at the intersection of two common and important cardiac disease sets. J Cardiovasc Electrophysiol. 2002;13(4):399-405. (Pubitemid 34407608)
34. Ryu K, Shroff SC, Sahadevan J, Martovitz NL, Khrestian CM, Stambler BS. Mapping of atrial activation during sustained atrial fibrillation in dogs with rapid ventricular pacing induced heart failure: evidence for a role of driver regions. J Cardiovasc Electrophysiol. 2005;16(12):1348-1358.
35. Stambler BS, Fenelon G, Shepard RK, Clemo HF, Guiraudon CM. Characterization of sustained atrial tachycardia in dogs with rapid ventricular pacing-induced heart failure. J Cardiovasc Electrophysiol. 2003;14(5):499-507. (Pubitemid 36583911)
36. Yeh YH, et al. Calcium-handling abnormalities underlying atrial arrhythmogenesis and contractile dysfunction in dogs with congestive heart failure. Circ Arrhythm Electrophysiol. 2008;1(2):93-102.
37. Saba S, et al. Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific overexpression of tumor necrosis factor-{alpha}. Am J Physiol Heart Circ Physiol. 2005;289(4):H1456-H1467. (Pubitemid 41368987)
38. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995;98(5):476-484.
39. Nishida K, et al. Mechanisms of atrial tachyarrhythmias associated with coronary artery occlusion in a chronic canine model. Circulation. 2011;123(2):137-146.
40. Sinno H, Derakhchan K, Libersan D, Merhi Y, Leung TK, Nattel S. Atrial ischemia promotes atrial fibrillation in dogs. Circulation. 2003;107(14):1930- 1936. (Pubitemid 36444137)
41. 2+ release in cardiomyocytes during beta-adrenergic stimulation. J Physiol. 2010;588(pt 1):225-242.
42. Tan AY, et al. Neural mechanisms of paroxysmal atrial fibrillation and paroxysmal atrial tachycardia in ambulatory canines. Circulation. 2008;118(9):916-925.
43. Choi EK, et al. Intrinsic cardiac nerve activity and paroxysmal atrial tachyarrhythmia in ambulatory dogs. Circulation. 2010;121(24):2615-2623.
44. Chou CC, et al. Intracellular calcium dynamics and acetylcholine-induced triggered activity in the pulmonary veins of dogs with pacing-induced heart failure. Heart Rhythm. 2008;5(8):1170-1177.
45. Mohler PJ, et al. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature. 2003;421(6923):634-639. (Pubitemid 36227671)
46. Nyberg MT, Stoevring B, Behr ER, Ravn LS, McKenna WJ, Christiansen M. The variation of the sarcolipin gene (SLN) in atrial fibrillation, long QT syndrome and sudden arrhythmic death syndrome. Clin Chim Acta. 2007;375(1-2):87-91. (Pubitemid 44584225)
47. Ehrlich JR, Zicha S, Coutu P, Hebert TE, Nattel S. Atrial fibrillation-associated minK38G/S polymorphism modulates delayed rectifier current and membrane localization. Cardiovasc Res. 2005;67(3):520-528. (Pubitemid 41019559)
48. Johnson JN, Tester DJ, Perry J, Salisbury BA, Reed CR, Ackerman MJ. Prevalence of early-onset atrial fibrillation in congenital long QT syndrome. Heart Rhythm. 2008;5(5):704-709.
49. Zellerhoff S, et al. Atrial Arrhythmias in long-QT syndrome under daily life conditions: a nested case control study. J Cardiovasc Electrophysiol. 2009;20(4):401-407.
50. Olson TM, et al. Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum Mol Genet. 2006;15(14):2185-2191. (Pubitemid 43985509)
51. Yang T, Yang P, Roden DM, Darbar D. Novel KCNA5 mutation implicates tyrosine kinase signaling in human atrial fibrillation. Heart Rhythm. 2010;7(9):1246-1252.
52. Blana A, et al. Knock-in gain-of-function sodium channel mutation prolongs atrial action potentials and alters atrial vulnerability. Heart Rhythm. 2010;7(12):1862-1869.
53. Lemoine MD, Qi XY, Chartier D, Fabritz L, Kirchhof P, Nattel S. Electrophysiological basis for atrial arrhythmia in a Long QT Syndrome mouse model. Circulation. 2010;122(1):A11401.
54. Li Q, et al. Gain-of-function mutation of Nav1.5 in atrial fibrillation enhances cellular excitability and lowers the threshold for action potential firing. Biochem Biophys Res Commun. 2009;380(1):132-137.
55. Makiyama T, et al. A novel SCN5A gain-of-function mutation M1875T associated with familial atrial fibrillation. J Am Coll Cardiol. 2008;52(16):1326-1334.
56. Gudbjartsson DF, et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature. 2007;448(7151):353-357. (Pubitemid 47080348)
57. Mommersteeg MT, et al. Pitx2c and Nkx2-5 are required for the formation and identity of the pulmonary myocardium. Circ Res. 2007;101(9):902-909. (Pubitemid 350287177)
58. Mommersteeg MT, et al. Molecular pathway for the localized formation of the sinoatrial node. Circ Res. 2007;100(3):354-362.
59. Ellinor PT, et al. Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet. 2010;42(3):240-244.
60. Ozgen N, et al. Early electrical remodeling in rabbit pulmonary vein results from trafficking of intracellular SK2 channels to membrane sites. Cardiovasc Res. 2007;75(4):758-769. (Pubitemid 47238736)
61. + channel (SK2 channel) results in action potential prolongation in atrial myocytes and atrial fibrillation. J Physiol. 2009;587(pt 5):1087-1100.
62. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 1995;92(7):1954-1968.
63. Shiroshita-Takeshita A, Mitamura H, Ogawa S, Nattel S. Rate-dependence of atrial tachycardia effects on atrial refractoriness and atrial fibrillation maintenance. Cardiovasc Res. 2009;81(1):90-97.
64. Yue L, Feng J, Gaspo R, Li GR, Wang Z, Nattel S. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res. 1997;81(4):512-525. (Pubitemid 27432738)
65. 2+ currents and human atrial fibrillation. Circ Res. 1999;85(5):428-436.
66. 2+ current downregulation in chronic human atrial fibrillation is associated with increased activity of protein phosphatases. Circulation. 2004;110(17):2651-2657.
67. Ehrlich JR, et al. Characterization of a hyperpolarization- activated time-dependent potassium current in canine cardiomyocytes from pulmonary vein myocardial sleeves and left atrium. J Physiol. 2004;557(pt 2):583-597. (Pubitemid 38807396)
68. K, ACh and muscarinic receptor-mediated shortening of action potentials. Circulation. 2001;104(21):2551-2557.
69. K, ACh is constitutively active in patients with chronic atrial fibrillation. Circulation. 2005;112(24):3697-3706.
70. Cha TJ, Ehrlich JR, Chartier D, Qi XY, Xiao L, Nattel S. Kir3-based inward rectifier potassium current: potential role in atrial tachycardia remodeling effects on atrial repolarization and arrhythmias. Circulation. 2006;113(14):1730-1737. (Pubitemid 43958465)
71. Voigt N, et al. Differential phosphorylationdependent regulation of constitutively active and muscarinic receptor-activated IK, ACh channels in patients with chronic atrial fibrillation. Cardiovasc Res. 2007;74(3):426-437. (Pubitemid 46693702)
72. Yue L, Melnyk P, Gaspo R, Wang Z, Nattel S. Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation. Circ Res. 1999;84(7):776-784. (Pubitemid 29181484)
73. Qi XY, et al. Cellular signaling underlying atrial tachycardia remodeling of L-type calcium current. Circ Res. 2008;103(8):845-854.
74. to in rapid atrial pacing in rabbits. J Am Coll Cardiol. 2003;41(5):858-869.
75. 2+-channel, beta-adrenorecptor, and 5- hydroxytryptamine type 4 receptor mRNAs in human atrial fibrillation. Basic Res Cardiol. 2001;96(1):82-90.
76. Carnes CA, et al. Atrial glutathione content, calcium current, and contractility. J Biol Chem. 2007;282(38):28063-28073. (Pubitemid 47529546)
77. Wang Z, Lu Y, Yang B. MicroRNAs and atrial fibrillation: new fundamentals. Cardiovasc Res. 2011;89(4):710-721.
78. Lu Y, et al. MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation. Circulation. 2010;122(23):2378-2387.
79. Levy S, et al. Molecular basis for zinc transporter 1 action as an endogenous inhibitor of L-type calcium channels. J Biol Chem. 2009;284(47):32434-32443.
80. Pandit SV, et al. Ionic determinants of functional reentry in a 2-D model of human atrial cells during simulated chronic atrial fibrillation. Biophys J. 2005;88(6):3806-3821. (Pubitemid 40991096)
81. Cha TJ, Ehrlich JR, Zhang L, Chartier D, Leung TK, Nattel S. Atrial tachycardia remodeling of pulmonary vein cardiomyocytes: comparison with left atrium and potential relation to arrhythmogenesis. Circulation. 2005;111(6):728-735. (Pubitemid 40250632)
82. Voigt N, et al. Changes in I K, ACh single-channel activity with atrial tachycardia remodelling in canine atrial cardiomyocytes. Cardiovasc Res. 2008;77(1):35-43. (Pubitemid 351195163)
83. Girmatsion Z, et al. Changes in microRNA-1 expression and IK1 up-regulation in human atrial fibrillation. Heart Rhythm. 2009;6(12):1802-1809.
84. Luo X, et al. Critical role of microRNAs miR-26 and miR-101 in atrial electrical remodeling in experimental atrial fibrillation. Circulation. 2010;122:A19435.
85. Karle CA, et al. Human cardiac inwardly-rectifying K+ channel Kir(2.1b) is inhibited by direct protein kinase C-dependent regulation in human isolated cardiomyocytes and in an expression system. Circulation. 2002;106(12):1493-1499.
86. Makary S, et al. Mechanisms underlying activation of constitutive acetylcholine-regulated potassium channels by atrial tachycardia remodeling. Circulation. 2009;120:S664.
87. Dhein S, et al. Improving cardiac gap junction communication as a new antiarrhythmic mechanism: the action of antiarrhythmic peptides. Naunyn Schmiedebergs Arch Pharmacol. 2010;381(3):221-234.
88. Nishida K, Michael G, Dobrev D, Nattel S. Animal models for atrial fibrillation: clinical insights and scientific opportunities. Europace. 2010;12(2):160-172.
89. Ausma J, et al. Reverse structural and gap-junctional remodeling after prolonged atrial fibrillation in the goat. Circulation. 2003;107(15):2051-2058. (Pubitemid 36506082)
90. Firouzi M, et al. Association of human connexin40 gene polymorphisms with atrial vulnerability as a risk factor for idiopathic atrial fibrillation. Circ Res. 2004;95(4):e29-e33.
91. Gollob MH, et al. Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. N Engl J Med. 2006;354(25):2677-2688.
92. Burstein B, et al. Changes in connexin expression and the atrial fibrillation substrate in congestive heart failure. Circ Res. 2009;105(12):1213-1222.
93. Bosch RF, Zeng X, Grammer JB, Popovic K, Mewis C, Kuhlkamp V. Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc Res. 1999;44(1):121-131. (Pubitemid 29431690)
94. + currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol. 2010;55(21):2330-2342.
95. Kneller J, Zou R, Vigmond EJ, Wang Z, Leon LJ, Nattel S. Cholinergic atrial fibrillation in a computer model of a two-dimensional sheet of canine atrial cells with realistic ionic properties. Circ Res. 2002;90(9):E73-E87.
96. KACh in atrial fibrillation using a mouse knockout model. J Am Coll Cardiol. 2001;37(8):2136-2143.
97. Chen YH, et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science. 2003;299(5604):251-254.
98. Hong K, Bjerregaard P, Gussak I, Brugada R. Short QT syndrome and atrial fibrillation caused by mutation in KCNH2. J Cardiovasc Electrophysiol. 2005;16(4):394-396.
99. Xia M, et al. A Kir2.1 gain-of-function mutation underlies familial atrial fibrillation. Biochem Biophys Res Commun. 2005;332(4):1012-1019. (Pubitemid 40798187)
100. Yang Y, et al. Identification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillation. Am J Hum Genet. 2004;75(5):899-905. (Pubitemid 39390498)
101. Antzelevitch C, et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation. 2007;115(4):442-449. (Pubitemid 46184195)
102. Hagendorff A, Schumacher B, Kirchhoff S, Luderitz B, Willecke K. Conduction disturbances and increased atrial vulnerability in Connexin40-deficient mice analyzed by transesophageal stimulation. Circulation. 1999;99(11):1508-1515. (Pubitemid 29140919)
103. Olson TM, et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAMA. 2005;293(4):447-454.
104. Chen LY, Ballew JD, Herron KJ, Rodeheffer RJ, Olson TM. A common polymorphism in SCN5A is associated with lone atrial fibrillation. Clin Pharmacol Ther. 2007;81(1):35-41. (Pubitemid 46050865)
105. Ellinor PT, Nam EG, Shea MA, Milan DJ, Ruskin JN, MacRae CA. Cardiac sodium channel mutation in atrial fibrillation. Heart Rhythm. 2008;5(1):99-105.
106. Francis J, Antzelevitch C. Atrial fibrillation and Brugada syndrome. J Am Coll Cardiol. 2008;51(12):1149-1153. (Pubitemid 351382100)
107. Watanabe H, et al. Mutations in sodium channel beta1- and beta2-subunits associated with atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;2(3):268-275.
108. Olesen MS, et al. Mutations in sodium channel {beta}-subunit SCN3B are associated with early-onset lone atrial fibrillation. Cardiovasc Res. 2011;89(4):786-793.
109. Fatini C, et al. Analysis of minK and eNOS genes as candidate loci for predisposition to non-valvular atrial fibrillation. Eur Heart J. 2006;27(14):1712-1718. (Pubitemid 44026432)
110. Elvan A, Rubart M, Zipes DP. NO modulates autonomic effects on sinus discharge rate and AV nodal conduction in open-chest dogs. Am J Physiol. 1997;272(1 pt 2):H263-H271.
111. 2+ current. Involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activation. J Biol Chem. 1993;268(35):26286-26295.
112. Benjamin EJ, et al. Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation. 2009;119(4):606-618.
113. Li D, Fareh S, Leung TK, Nattel S. Promotion ofatrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation. 1999; 100(1):87-95. (Pubitemid 29297945)
114. Lamirault G, et al. Gene expression profile associated with chronic atrial fibrillation and underlying valvular heart disease in man. J Mol Cell Cardiol. 2006;40(1):173-184. (Pubitemid 43012128)
115. Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J. 2006;27(5):512-518.
116. He X, et al. Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific arkadia-mediated downregulation of Smad7. Circ Res. 2011;108(2):164-175.
117. Koinuma D, et al. Arkadia amplifies TGF-beta superfamily signalling through degradation of Smad7. EMBO J. 2003;22(24):6458-6470. (Pubitemid 38009594)
118. Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol. 2006;20(5):953-970.
119. Burstein B, Libby E, Calderone A, Nattel S. Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences. Circulation. 2008;117(13):1630-1641. (Pubitemid 351482606)
120. Verheule S, et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res. 2004;94(11):1458-1465. (Pubitemid 38780318)
121. Burstein B, Qi XY, Yeh YH, Calderone A, Nattel S. Atrial cardiomyocyte tachycardia alters cardiac fibroblast function: a novel consideration in atrial remodeling. Cardiovasc Res. 2007;76(3):442-452. (Pubitemid 350007456)
122. Tsai CT, et al. Tachycardia of atrial myocytes induces collagen expression in atrial fibroblasts through transforming growth factor {beta}1. Cardiovasc Res. 2011;89(4):805-815.
123. Ponten A, Folestad EB, Pietras K, Eriksson U. Platelet- derived growth factor D induces cardiac fibrosis and proliferation of vascular smooth muscle cells in heart-specific transgenic mice. Circ Res. 2005;97(10):1036-1045. (Pubitemid 41668917)
124. Liao CH, et al. Cardiac mast cells cause atrial fibrillation through PDGF-A-mediated fibrosis in pressure-overloaded mouse hearts. J Clin Invest. 2004;120(1):242-253.
125. Ahmed MS, et al. Connective tissue growth factor - a novel mediator of angiotensin II-stimulated cardiac fibroblast activation in heart failure in rats. J Mol Cell Cardiol. 2004;36(3):393-404. (Pubitemid 38316944)
126. Cardin S, et al. Contrasting gene expression profiles in two canine models of atrial fibrillation. Circ Res. 2007;100(3):425-433.
127. Adam O, et al. Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation. J Am Coll Cardiol. 2010;55(5):469-480.
128. van Rooij E, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A. 2008;105(35):13027-13032.
129. Dawson K, et al. Potential role of MicroRNA-29b in atrial fibrillation-promoting fibrotic remodeling. Circulation. 2010;122:A12545.
130. Duisters RF, et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res. 2009;104(2):170-178.
131. Chen Y, et al. MicroRNA changes and atrial arrhythmogenic remodeling in tachycardiomyopathic heart failure. Circulation. 2010;122:A12988.
132. Thum T, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008;456(7224):980- 984.
133. Patrick DM, et al. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J Clin Invest. 2010;120(11):3912-3916.
134. Kannel WB, Benjamin EJ. Current perceptions of the epidemiology of atrial fibrillation. Cardiol Clin. 2009;27(1):13-24, vii.
135. Kato T, et al. AGEs-RAGE system mediates atrial structural remodeling in the diabetic rat. J Cardiovasc Electrophysiol. 2008;19(4):415-420. (Pubitemid 351457548)
136. Fatini C, et al. Lone and secondary nonvalvular atrial fibrillation: role of a genetic susceptibility. Int J Cardiol. 2007;120(1):59-65. (Pubitemid 47008994)
137. Kato K, et al. Genetic factors for lone atrial fibrillation. Int J Mol Med. 2007;19(6):933-939.
138. Benjamin EJ, et al. Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nat Genet. 2009;41(8):879-881.
139. Kim CJ, et al. Down-regulation of ATBF1 is a major inactivating mechanism in hepatocellular carcinoma. Histopathology. 2008;52(5):552-559. (Pubitemid 351442655)
140. Kim TS, et al. The ZFHX3 (ATBF1) transcription factor induces PDGFRB, which activates ATM in the cytoplasm to protect cerebellar neurons from oxidative stress. Dis Model Mech. 2010;3(11-12):752-762.
141. Chen LY, Shen WK. Epidemiology of atrial fibrillation: a current perspective. Heart Rhythm. 2007;4(3 suppl):S1-S6.
142. Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace. 2011;13(3):308-328.
143. Machida T, et al. Effects of a highly selective acetylcholine- activated K+ channel blocker on experimental atrial fibrillation. Circ Arrhythm Electrophysiol. 2011;4(1):94-102.
144. + channels terminates and protects against atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3(4):380-390.
145. Amit G, Kikuchi K, Greener ID, Yang L, Novack V, Donahue JK. Selective molecular potassium channel blockade prevents atrial fibrillation. Circulation. 2010;121(21):2263-2270.
146. Cheng Y, Zhan Q, Zhao J, Xiao J. Stabilizing ryanodine receptor type 2: a novel strategy for the treatment of atrial fibrillation. Med Sci Monit. 2010;16(7):HY23-JY26.
147. Kushnir A, Marks AR. The ryanodine receptor in cardiac physiology and disease. Adv Pharmacol. 2010;59:1-30.
148. Seok HY, Wang DZ. The emerging role of microRNAs as a therapeutic target for cardiovascular disease. BioDrugs. 2010;24(3):147-155.
149. Daccarett M, McGann CJ, Akoum NW, MacLeod RS, Marrouche NF. MRI of the left atrium: predicting clinical outcomes in patients with atrial fibrillation. Expert Rev Cardiovasc Ther. 2011;9(1):105-111.
150. Latini R, et al., on the behalf of the GISSI-AF Investigators. Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-atrial fibrillation trial. J Intern Med. 2011;269(2):160-171.